cyrilzakka/clinical-trials huggingface dataset:
Clinical Effects in Cervical Spinal Mobilization and Oscillation Mobilization in Neck Pain

The aim of this study is to compare the clinical effects of spinal mobilization versus vertebral resonant oscillation (POLD) in patients with bilateral mechanical neck pain on pain sensitivity and neck pain intensity.

The clinical practice guidelines for manual therapy management the neck pain including the spine mobilization.

The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to "neutral zone" to described by Panjabi 1992.

The spinal mobilizations has a posterior-anterior vertebral movement for spinous process, described by Maitland 2000.

Eligibility Criteria:
Inclusion Criteria:

* neck pain symptoms of mechanical nature
* age from 18 to 60 years
* bilateral symptoms
* symptoms for at least 3 month of duration

Exclusion Criteria:

* whiplash injury
* previous spine surgery
* diagnosis of cervical radiculopathy or myelopathy
* having undergone any physical therapy intervention in the previous 6 month
* pregnancy
The Effect of 360° Virtual Reality Movies on Fear and Anxiety

To assess the effect of web-based 360° Virtual Reality movies on fear and anxiety, The investigators would like to assess the patient-perceived level of fear and anxiety quantitatively, making use of several questionnaires.

In ENGAGE, a KWF Samenloop Voor Hoop subsidized project, we have developed VR movies to reduce fear and anxiety for patients who are going to be treated at Maastro. These movies are based on where most fear and anxiety are experienced and have been developed after extensive discussion with different disciplines in patient care and with agreement of the Director Patient Care. The movies include: 1) Mouldroom, 2) VMDIBH mamma photons, 3) Head and Neck photons, 4) Lung photons, 5) CT-scan, 6) Prostate photons, and 7) Head and Neck/ Neuro protons. Currently, the web-based 360° movies are implemented in clinical practice and the VR glasses with the 360° movies will be used as soon as social work has decided on where to integrate the use in the care pathway.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with breast- (only VMDIP), lung-, prostate-, head and neck cancer, a brain tumor.
* Age 18+
* Being able to speak, read and write in Dutch
* General interview between radiation oncologist and patient (= Intake)
* Ability to give written informed consent before the start of the study
* Decision talk about start of treatment must have taken place

Exclusion Criteria:

* Patients who are already receiving radiotherapy treatment
* Pre-operative consultation for breast cancer patients
* Patients who have seen the VR-videos already
Osteopathic Manipulative Treatment for Constipation in People With Rett Syndrome

Constipation consists of bowel symptoms characterized by difficulty or infrequency passage of stool, stiff stool, or a feeling of incomplete evacuation. However, its impact goes far beyond this definition. Constipation negatively impacts the quality of life (QoL) of children and adults suffering from this condition, affecting mental and physical-related QoL. Additionally, a negative impact of constipation on QoL was found in parents carrying children with constipation, affecting family functioning.

People with an intellectual disability present a constipation rate of over 33%. Rett syndrome (RTT) is a complex neurodevelopmental disorder affecting about 1/10,000 females and a few males worldwide. Chronic constipation is persistent in people with RTT, with a reported prevalence higher than 74%.

Specific recommendations for constipation management in RTT were developed, including behavioral, pharmacological, and surgical considerations. Recently, the literature has been enriched with papers describing the osteopathic treatment efficacy in reducing constipation. Emerging literature reported the efficacy of OMT in reducing constipation symptoms and improving QoL in typically developed people, as well as in children with disability. The present study aims to evaluate the efficacy of a specific OMT for managing chronic constipation in people with RTT and its impact on primary caregivers' quality of life.

Research questions:

* Can an OMT improve the constipation of people with RTT, increasing the frequency of bowel movements?
* Can the effects of an OMT aimed at reducing the constipation symptoms in people with RTT positively impact the participants' parents' constipation-related QoL?

Twelve individuals with RTT and their families will be recruited to participate in this single-blind parallel group-randomized study. Participants will be randomly divided into an experimental group (EG) and a control group (CG). After the preliminary evaluations, each participant will undergo eight OMT carried out weekly for eight weeks. The OMT will aim to facilitate bowel movements by increasing blood flow through the abdomen. At the end of the treatment, the participants will repeat the evaluation conducted before the OMT, and the collected data will be analyzed.


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of classic Rett syndrome with a mutation of the MECP2 gene;
* matching the ROME IV criteria for constipation;

Exclusion Criteria:

* the presence of specific severe heart and cardiovascular diseases;
* the presence of amenorrhea.
Advanced HIV Prevention (PrEP Chicago)

This study will evaluate the feasibility of a network intervention to train individuals to disseminate PrEP information and motivate initial PrEP interest and knowledge of PrEP in their social networks.

The specific aims of this study are:

1. To recruit 450 participants in Chicago, Illinois, and to train them as peer change agents (randomized to cross-over groups) to disseminate PrEP information and motivate PrEP interest and knowledge of PrEP in their local networks.
2. To evaluate feasibility of the program over 2 years of participant follow-up through: 1) peer change agent exit survey; 2) peer change agent booster sessions; 3) peer change agent communication with University of Chicago PrEP program social media; 4) referrals into the project and; 5) calls into the PrEP warmline.

Eligibility Criteria:
Inclusion Criteria:

* Lives on the South Side of Chicago, Illinois
* Born male
* Has had sex with men in the previous year
* Is an active Facebook user
* Does not have plans to leave Chicago

Exclusion Criteria:

-
Validation of Safety and Efficacy for Night Shift Therapy

The purpose of this study is to assess the accuracy of Night Shift in the detection of supine sleep and efficacy of vibro-tactile feedback in restricting supine sleep.

The protocol is designed to first evaluate the accuracy of supine vs. non-supine detection in 15 subjects (hereafter referred to as study 1). In study 2, patients who had completed a baseline polysomnography (PSG) with a minimum of four hours of sleep time were to wear the Night Shift for two nights without feedback to confirm their willingness to continue with the study, followed by 28 nights of vibro-tactile position therapy. A follow-up PSG was to be conducted as soon as possible to the completion of the 28-nights of treatment. During enrollment subjects were to complete pre-treatment questionnaires designed to measure daytime sleepiness, insomnia severity, depression, anxiety, and quality of life. The same instruments were completed post-treatment on the morning after the 28th night of treatment. Subjects completed daily logs to confirm device utilization and identify potential non-device related factors that could influence study completion.

Eligibility Criteria:
The inclusion criteria are:

* be between the age of 18 and 75 years,
* have been diagnosed with Obstructive Sleep Apnea (OSA) during polysomnography at a designated sleep center within 4 months of their enrollment,
* have not received treatment with any OSA therapy for more than 3 days within the past month,
* have an overall Apnea-Hypopnea Index (AHI) \> 10 and hypopneas requiring \>3% oxygen desaturation,
* having a non-supine Apnea-Hypopnea Index (AHI) \< 15 if Continuous Positive Airway Pressure has not been attempted,
* have a overall AHI divided by the non-supine AHI \> 1.5,
* had an Epworth Sleepiness Score of 5 or more at the time of diagnosis and at the start of therapy,
* Change in weight of no more than 5 pounds since the diagnostic PSG
* access to a computer and the Internet
* sleep is sometime between 8 P.M. to 9 A.M. Monday through Friday in the same bed

Exclusion Criteria:

* Neck, back or should pain which would impact ability to sleep laterally each night
* Body mass index \> 35
* suffering from neurological disorders which result in ticks or tremors
* diagnosed with congestive heart failure or chronic obstructive pulmonary disease
* suffered from a stroke within the previous 12 months
* taking or planning to take narcotic medications
* unfamiliar with use of internet browsers
* travel (i.e., foreign or cruise ship) which would limit internet or mail access
* planned medical procedures (e.g., surgery) which would limit device use during the scheduled 30-day study period or introduce the need for narcotic pain medications
A Study in Healthy People to Test How 3 Different Formulations of BI 764198 Are Taken up in the Body and How This is Influenced by Food

This trial aims to investigate the relative bioavailability of three different oral formulations of BI 764198 and how this is influenced by food.


Eligibility Criteria:
Inclusion criteria:

* Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests
* Age of 18 to 55 years (inclusive)
* Body Mass Index (BMI) of 18.5 to 29.9 kg/m² (inclusive)
* Signed and dated written informed consent in accordance with the International Council for Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial Further inclusion criteria apply.

Exclusion criteria:

* Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
* Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
* Any evidence of a concomitant disease assessed as clinically relevant by the investigator Further exclusion criteria apply.
The Effect of Tang Ning Tongluo Formula in Type 2 Diabetics Clinical Analysis

The aim of this retrospective study is to review and describe safety and efficacy of Tang Ning Tong Luo capsule.

The aim of this retrospective study is to review and describe safety and efficacy of Tang Ning Tong Luo capsule,a traditional Chinese Miao medicine, in Type 2 Diabetics.

Eligibility Criteria:
Inclusion criteria:

1. diagnosis of type 2 diabetes for more than one year.
2. the sustained follow-up time \>3 month.
3. TNTL single or combined treatment time \>3 month.
4. Chinese ethnicity.

Exclusion criteria:

1. the medical record information is not original and available.
2. lactating or pregnant.
3. diagnosis of heart failure, acute myocardial infarction, stroke, or serious injuries.
4. any other conditions not suitable for trial as evaluated by the physician in charge.
Sex Differences in the effecTs of brEaking uP Sedentary Behavior on vascUlar Function in Type 2 Diabetes

Type 2 diabetes (T2D) confers a high risk of cardiovascular disease (CVD), particularly among older adults who tend to be physically inactive. Prolonged sedentary behavior (SB) has been shown to negatively influence markers of cardiovascular risk (e.g., blood glucose, blood pressure), even among individuals who are physically active. Most studies that have examined the effects of breaking up SB have focused on young healthy males and prioritized glycemic outcomes. Additionally, sex differences in these outcomes have not been adequately examined. The present study will address these gaps. This 3-arm crossover randomized controlled trial will compare the effects of 3 SB conditions on markers of vascular function. The 3 conditions are: 1) 4 hours of prolonged SB, 2) 4 hours of SB broken up by 5 minutes of self-paced walking every hour, and 3) 4 hours of SB with one 20-minute bout of self-paced walking. In addition to examining the overall effects of each condition, sex differences in physiological responses will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥60 years
* Postmenopausal (females only, ≥12 months without a menstrual period)
* Type 2 diabetes (hemoglobin A1c ≥6.5% and/or previous diagnosis of type 2 diabetes)
* ≥6 hours/day sedentary (assessed via IPAQ)
* Willingness to abstain from food, caffeine, alcohol and exercise for \>= 24 hours, and tobacco/smoking for ≥12 hours prior to each intervention visit
* Ability to speak and read English

Exclusion Criteria:

* Type 1 diabetes
* Uncontrolled hypertension (resting systolic ≥160 or diastolic ≥110 mmHg)
* Initiation of hormone therapy or change in hormone therapy dose/frequency/route of administration in the previous 3 months
* Renal dialysis
* History of deep vein thrombosis (DVT)
* Evidence of cognitive impairment that could impact ability to consent and/or participation (Mini-Cog score \<3)
* Achieving physical activity guidelines (≥150 minutes of MVPA/week, assessed via IPAQ))
* Physical impairment or disability that interferes with ability to engage in PA (e.g., severe osteoarthritis, lower extremity amputation \[other than toe(s)/partial foot\], use of a walker or wheelchair, etc.),
* Unstable medical/psychiatric condition that could impact study participation
A Prospective, Multicenter, Randomized, Comparator-controlled, Evaluator-blinded Study to Evaluate the Safety and Effectiveness of VP1 Lido US for Volume Augmentation of the Cheek

The primary objective of the study is to demonstrate non-inferiority of VP1 Lido US versus an approved hyaluronic acid dermal filler following deep (subdermal and/or supraperiosteal) injection of the cheek for volume augmentation.


Eligibility Criteria:
Inclusion Criteria:

* Has a symmetrical rating of 2 (moderate) or 3 (severe) for right and left cheek on the Merz Cheeks Fullness Assessment Scale (MCFAS)
* Desires cheek augmentation to correct volume deficit in the midface and is willing to receive sufficient volume to achieve at least a 1-point improvement on the MCFAS

Exclusion Criteria:

* Skin or fat atrophy in the midfacial region other than that related to age.
* Subjects with body mass index of \<18.5 or ≥30
* Acute inflammatory process or active infection at the injection site (e.g., acne, eczema, streptococcus infections), or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of AEs.
* Prior surgery, including midfacial plastic surgery, or has a permanent implant or graft in the midfacial region that could interfere with effectiveness assessments.
* Received midfacial region treatments with porcine-based collagen fillers or with RADIESSE® or with volumizing hyaluronic acid fillers such as but not limited to Juvéderm® Voluma, Restylane® Lyft within the past 24 months and/or with other HA fillers or mesotherapy within the past 12 months or plans to receive such treatments during participation in the study.
* Received facial dermal therapies (i.e., facial ablative or fractional laser, dermabrasion, chemical peels, non-invasive skin-tightening \[e.g., Ultherapy®, Thermage®\] and surgical procedures) in the midfacial region within the past 12 months or plans to receive them in the facial region during participation in the study.
A Study of LY4060874 in Healthy Participants

The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants.

Study participation may last up to 22 weeks and up to approximately 16 study visits.


Eligibility Criteria:
Inclusion Criteria:

* Are overtly healthy as determined by medical evaluation, including medical history and physical examination.
* Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening.
* To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
* To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.

Exclusion Criteria:

* Have a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus.
* Have hemoglobin A1c (HbA1c) \> 6.4% or 46 millimoles/mole (mmol/mol) at screening.
* Have taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening.
* Have had surgical treatment for obesity.
* Are actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.
Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)

Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine and Typhoid Vi polysaccharide vaccine.

Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine and to Typhoid Vi polysaccharide vaccine.

Involved participants aged 6 months old to 60 years old.

Eligibility Criteria:
Inclusion Criteria:

* Healthy.
* Subject/Parents/legal guardian(s) have been informed properly regarding the study and signed the informed consent form/and informed assent form.
* Subject/parents/legal guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.

Exclusion Criteria:

* Subject concomitantly enrolled or scheduled to be enrolled in another trial.
* Evolving mild, moderate or severe illness, especially infectious diseases or fever (axilary temperature ³ 37.5°C).
* Known history of allergy to any component of the vaccines.
* History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection.
* Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, corticosteroid therapy and other immunosuppressants)
* Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
* Pregnancy \& lactation (Adults).
* Individuals who have previously received any vaccines against typhoid fever.
* Subjects already vaccinated with any vaccine within one month prior and expect to receive other vaccines within one month following vaccination except MR (Measles Rubella) vaccine.
* Individuals who have a previously ascertained typhoid fever by laboratory confirmation (blood culture/new rapid test) at any time.
* Subject planning to move from the study area before the end of study period.
Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of UPJO

Renal blood flow is inversely related to obstruction. We propose that this imaging will be as effective as the diuretic renogram in the functional diagnosis of obstruction. Furthermore, dynamic contrast CT scanning may also add anatomic information necessary for the surgical treatment.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older;
* Subjects suspected to have UPJO.

Exclusion Criteria:

* Pregnancy;
* Renal failure (Creatinine \>150);
* Allergy to contrast material;
* Ureteral stent;
* Nephrostomy tube;
* Renal pelvis calculi.
Protect Chronic Tibial Nerve Stimulator (CTNS) System

30 patient Study. All patients implanted with StimGuard Protect System. Patient followed out to 90 days.

The proposed therapy is called chronic tibial nerve stimulation (CTNS), which is a low-risk, minimally invasive chronic implant for the treatment of urgency urinary incontinence. CTNS works by the same mechanism as percutaneous tibial nerve stimulation (PTNS), but is provided for chronic use with an implantable device. CTNS treatment involves the placement of a minimally invasive stimulator with an embedded receiver at the tibial nerve. The Protect CTNS System has an external transmitter that activates the implanted stimulator and sends mild electrical pulses to the tibial nerve. These impulses travel to the sacral nerve plexus, the group of nerves at the base of the spine responsible for bladder function. Since stimulation with the Protect CTNS System is chronic it is expected that bladder activity can be changed more quickly and without the frequency of treatments related to PTNS.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of overactive bladder with urgency urinary incontinence

Exclusion Criteria:

* Primary complaint of stress urinary incontinence
Virtual Reality in Motor Neurone Disease

Motor Neurone Disease (MND) is a chronic progressive neurological condition where people experience weakness of muscles leading to pain and restriction of movement as well as problems with swallowing, breathing and communication. The purpose of this study is to establish if Virtual Reality is useful for people with MND and if it helps improve their well being.

Motor Neurone Disease (MND) is a chronic progressive neurological condition where people experience weakness of muscles leading to pain and restriction of movement as well as problems with swallowing, breathing and communication.

As people become increasingly immobile, they become restricted in their ability to perform activities of daily living, access the outdoors, participate in preferred occupational roles or engage in leisure activities. Consequently, there is a deterioration in their ability to experience well being and have quality of life. There is also a significant carer burden as the carer spends long hours in the day looking after the person. The average disease trajectory lasts between 3-5 years, followed by death. More recently, the use of Virtual Reality (VR) technology is being recognised in the field of health. This technology uses the interactions between an individual and a computer generated environment to stimulate different sensory modalities such as visual and auditory. The technology can be accessed commonly using head mounted goggles or head sets. The entertaining or stimulating effect of VR is useful in redirecting the person's attention away from the distressing experiences, such as pain and anxiety. The purpose of this study is to establish if VR is useful for people with MND and if it helps improve their well being.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of MND
2. Sufficient cognitive ability to understand instructions with regards using the VR kit (ECAS score - minimum 100/136)
3. Has sufficient motor ability/dexterity to use the kit or a carer who will be able to assist with the use of the kit.
4. Can tolerate light and have sufficient head control to wear the head set.
5. English speaking

Exclusion Criteria:

1. Poor cognition - inability to understand instructions regarding the use of VR (Total ECAS Score \<100/136)
2. Unable to tolerate light/unable to wear the head set
3. Light sensitive epilepsy, severe vertigo or dizziness.
4. Non English speaking